These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

608 related articles for article (PubMed ID: 19406341)

  • 1. Differences in restenosis rate with different drug-eluting stents in patients with and without diabetes mellitus: a report from the SCAAR (Swedish Angiography and Angioplasty Registry).
    Fröbert O; Lagerqvist B; Carlsson J; Lindbäck J; Stenestrand U; James SK
    J Am Coll Cardiol; 2009 May; 53(18):1660-7. PubMed ID: 19406341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease.
    Mehilli J; Kastrati A; Byrne RA; Bruskina O; Iijima R; Schulz S; Pache J; Seyfarth M; Massberg S; Laugwitz KL; Dirschinger J; Schömig A;
    J Am Coll Cardiol; 2009 May; 53(19):1760-8. PubMed ID: 19422982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.
    Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K
    Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lower risk of stent thrombosis and restenosis with unrestricted use of 'new-generation' drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR).
    Sarno G; Lagerqvist B; Fröbert O; Nilsson J; Olivecrona G; Omerovic E; Saleh N; Venetzanos D; James S
    Eur Heart J; 2012 Mar; 33(5):606-13. PubMed ID: 22232428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sirolimus, Tacrolimus and Zotarolimus eluting stents to treat bifurcated lesions: a 7-month clinical outcome comparison.
    Brugaletta S; Burzotta F; Trani C; Todaro D; Talarico G; Porto I; Leone AM; Niccoli G; Mazzari MA; Mongiardo R; Schiavoni G; Crea F
    Minerva Cardioangiol; 2008 Feb; 56(1):35-42. PubMed ID: 18432167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2-year clinical outcomes after implantation of sirolimus-eluting, paclitaxel-eluting, and bare-metal coronary stents: results from the WDHR (Western Denmark Heart Registry).
    Kaltoft A; Jensen LO; Maeng M; Tilsted HH; Thayssen P; Bøttcher M; Lassen JF; Krusell LR; Rasmussen K; Hansen KN; Pedersen L; Johnsen SP; Sørensen HT; Thuesen L
    J Am Coll Cardiol; 2009 Feb; 53(8):658-64. PubMed ID: 19232897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients.
    Dibra A; Kastrati A; Mehilli J; Pache J; Schühlen H; von Beckerath N; Ulm K; Wessely R; Dirschinger J; Schömig A;
    N Engl J Med; 2005 Aug; 353(7):663-70. PubMed ID: 16105990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-eluting or bare-metal stenting in patients with diabetes mellitus: results from the Massachusetts Data Analysis Center Registry.
    Garg P; Normand SL; Silbaugh TS; Wolf RE; Zelevinsky K; Lovett A; Varma MR; Zhou Z; Mauri L
    Circulation; 2008 Nov; 118(22):2277-85, 7p following 2285. PubMed ID: 19001019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictor of subsequent target lesion revascularization in patients with drug-eluting stent restenosis undergoing percutaneous coronary intervention.
    Takasawa Y; Iijima R; Shiba M; Nakamura M; Sugi K
    J Cardiol; 2010 May; 55(3):391-6. PubMed ID: 20350511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coronary in-stent restenosis in diabetic patients after implantation of sirolimus or paclitaxel drug-eluting coronary stents.
    Kitoga M; Pasquet A; Preumont V; Kefer J; Hermans MP; Vanoverschelde JL; Buysschaert M
    Diabetes Metab; 2008 Feb; 34(1):62-7. PubMed ID: 18069029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis of randomized trials of drug-eluting stents versus bare metal stents in patients with diabetes mellitus.
    Boyden TF; Nallamothu BK; Moscucci M; Chan PS; Grossman PM; Tsai TT; Chetcuti SJ; Bates ER; Gurm HS
    Am J Cardiol; 2007 May; 99(10):1399-402. PubMed ID: 17493468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel versus sirolimus stents in diabetic and nondiabetic patients.
    Chiu M; Ko DT; Austin PC; Cohen EA; Velianou JL; Goeree R; Blackhouse G; Tu JV
    Circ Cardiovasc Qual Outcomes; 2009 Mar; 2(2):96-107. PubMed ID: 20031821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Drug-eluting stents for diabetic patients. A critical appraisal of the currently available data from randomized trials].
    Silber S; Herdeg C
    Herz; 2008 Apr; 33(3):196-205. PubMed ID: 18568314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial clinical experience with an everolimus eluting platinum chromium stent (Promus Element) in unselected patients from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).
    Sarno G; Lagerqvist B; Carlsson J; Olivecrona G; Nilsson J; Calais F; Götberg M; Nilsson T; Sjögren I; James S
    Int J Cardiol; 2013 Jul; 167(1):146-50. PubMed ID: 22244480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Head-to-head comparison of sirolimus- and paclitaxel-eluting stent in the same diabetic patient with multiple coronary artery lesions: a prospective, randomized, multicenter study.
    Tomai F; Reimers B; De Luca L; Galassi AR; Gaspardone A; Ghini AS; Ferrero V; Favero L; Gioffrè G; Prati F; Tamburino C; Ribichini F
    Diabetes Care; 2008 Jan; 31(1):15-9. PubMed ID: 17909090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The everolimus-eluting stent in real-world patients: 6-month follow-up of the X-SEARCH (Xience V Stent Evaluated at Rotterdam Cardiac Hospital) registry.
    Onuma Y; Kukreja N; Piazza N; Eindhoven J; Girasis C; Schenkeveld L; van Domburg R; Serruys PW;
    J Am Coll Cardiol; 2009 Jul; 54(3):269-76. PubMed ID: 19589442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy and safety of Zotarolimus-eluting stent in patients with diabetes mellitus: pooled 5-year results from the ENDEAVOR III and IV trials.
    Vardi M; Burke DA; Bangalore S; Pencina MJ; Mauri L; Kandzari DE; Leon MB; Cutlip DE
    Catheter Cardiovasc Interv; 2013 Dec; 82(7):1031-8. PubMed ID: 23737390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of the tacrolimus drug-eluting Janus stent: a prospective two-centre registry in high-risk patients.
    Romagnoli E; Leone AM; Burzotta F; Trani C; Angeloni G; Materazzo G; Niccoli G; De Vita M; Perfetti M; Mazzari MA; Mongiardo R; Rebuzzi AG; Schiavoni G; Crea F
    J Cardiovasc Med (Hagerstown); 2008 Jun; 9(6):589-94. PubMed ID: 18475127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term clinical outcomes of sirolimus- versus paclitaxel-eluting stents for patients with unprotected left main coronary artery disease: analysis of the MAIN-COMPARE (revascularization for unprotected left main coronary artery stenosis: comparison of percutaneous coronary angioplasty versus surgical revascularization) registry.
    Lee JY; Park DW; Yun SC; Lee SW; Kim YH; Lee CW; Hong MK; Park SW; Park SJ
    J Am Coll Cardiol; 2009 Aug; 54(9):853-9. PubMed ID: 19695467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "Real life" use of sirolimus-eluting coronary stents in Germany. Results from the prospective multi-centre German Cypher Registry.
    Zahn R; Hamm CW; Zeymer U; Schneider S; Nienaber CA; Richardt G; Kelm M; Levenson B; Bonzel T; Tebbe U; Schöbel WA; Sabin G; Senges J
    Z Kardiol; 2004 Apr; 93(4):287-94. PubMed ID: 15085373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.